A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...

New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense challenge for patients, managing the emotional, logistical and personal burdens ...

Three Georgia companies and their principals have been banned from continuing their "bogus claims" that their stem cell ...

In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of ...

Cancer is a multifactorial disease that affects millions of individuals worldwide and has a profound impact on public health. The heterogeneity of solid ...

The company has three clinical CAR-T programmes backed by its precision-targeting cellular system Imod platform technology.

Led by first author Dr. Ahmed Gad, postdoctoral associate in Ahmed’s lab, the research team examined molecular dynamics at ...

A new study has introduced an innovative approach to CAR-T therapy that could address some of the current challenges in ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...